InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) has achieved a significant milestone by enrolling 15 patients in the INSPIRE 2.0 Study, representing 75% of its 20-patient enrollment target. This randomized, controlled trial aims to build on the clinical evidence for the Neuro-Spinal Scaffold™ developed from the previous INSPIRE 1.0 study. CEO Richard Toselli emphasized the importance of this progress amidst the challenges posed by the COVID-19 pandemic, reaffirming the company's commitment to addressing unmet medical needs in spinal cord injury treatments.
InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) announced the FDA's acceptance of its preclinical module for a humanitarian device exemption (HDE) application related to the Neuro-Spinal Scaffold™ implant. This marks a significant step, as it confirms the FDA has no further questions regarding this module. The HDE submission requires two more modules: manufacturing and clinical data. InVivo is also currently enrolling patients for its pivotal INSPIRE 2.0 trial, aimed at expanding clinical evidence for the Neuro-Spinal Scaffold™.
InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) announced its virtual Annual Meeting of Stockholders on July 16, 2021, urging stockholders to vote to achieve a quorum. Shareholders holding common stock by May 17, 2021, are entitled to participate. The company seeks approval for several proxy proposals, including the increase of authorized shares, aimed at facilitating capital-raising activities. While no immediate share issuance is planned, InVivo emphasizes the importance of this flexibility for future operations and investments.
InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) announces that Richard Toselli, M.D., President and CEO, will present at the M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference from March 17 – March 19, 2021. The presentation aims to provide an overview of the company and discuss key business updates. A webcast will be available for registered attendees starting March 17 at 9:00 am ET. The company focuses on treating spinal cord injuries, utilizing proprietary technology co-invented by leading figures in the field.
InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) has announced that Dr. Richard Toselli, President and CEO, will present at the 2021 H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. The presentation will provide an overview of the company and key business updates. Attendees can access the webcast starting March 9, 2021, at 7:00 am ET on the company’s Investor Relations website. InVivo focuses on treating spinal cord injuries and was founded in 2005 with technology co-invented by notable figures in the biotechnology field.
InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) announced the publication of a peer-reviewed manuscript in the Journal of Neurosurgery: Spine, detailing the results of the six-month INSPIRE 1.0 study on its Neuro-Spinal Scaffold for spinal cord injury. The company has closed the INSPIRE 1.0 study and is enrolling patients for a second pivotal trial, INSPIRE 2.0, aimed at further validating its treatment method. This new study will involve 20 patients and aims to enhance clinical evidence supporting the Neuro-Spinal Scaffold. The publication can be accessed electronically.
InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) has successfully closed a public offering of 18,750,000 shares of common stock and associated warrants, generating gross proceeds of $15 million at an effective price of $0.80 per share. H.C. Wainwright & Co. served as the exclusive placement agent for the offering. The offering was conducted under a registration statement filed with the SEC, declared effective on October 22, 2020. This strategic move aims to support the company's ongoing efforts in spinal cord injury treatment.
InVivo Therapeutics Holdings Corp. (NVIV) announced a public offering of 18,750,000 shares of common stock at an effective price of $0.80 per share. The offering, expected to close around October 26, 2020, aims to raise approximately $15 million, before agent fees and expenses. Each warrant included in the offering is exercisable at the same price and expires in five years. H.C. Wainwright & Co. serves as the exclusive placement agent. A registration statement related to the offering has been declared effective by the SEC.